Gender-stratified gene and gene-treatment interactions in smoking cessation by Lee W, Bergen A W, Swan G E, Li D, Liu J, Thomas P, Tyndale R F, Benowitz N L, Lerman C, Conti D V in The pharmacogenomics journal (2011).

[PMID: 21808284] PubMed


We conducted gender-stratified analyses on a systems-based candidate gene study of 53 regions involved in nicotinic response and the brain-reward pathway in two randomized clinical trials of smoking cessation treatments (placebo, bupropion, transdermal and nasal spray nicotine replacement therapy). We adjusted P-values for multiple correlated tests, and used a Bonferroni-corrected alpha-level of 5 × 10(-4) to determine system-wide significance. Four single-nucleotide polymorphisms (rs12021667, rs12027267, rs6702335, rs12039988; r(2)>0.98) in erythrocyte membrane protein band 4.1 (EPB41) had a significant male-specific marginal association with smoking abstinence (odds ratio (OR)=0.5; 95% confidence interval (CI): 0.3-0.6) at end of treatment (adjusted P<6 × 10(-5)). rs806365 in cannabinoid receptor 1 (CNR1) had a significant male-specific gene-treatment interaction at 6-month follow-up (adjusted P=3.9 × 10(-5)); within males using nasal spray, rs806365 was associated with a decrease in odds of abstinence (OR=0.04; 95% CI: 0.01-0.2). While the role of CNR1 in substance abuse has been well studied, we report EPB41 for the first time in the nicotine literature.The Pharmacogenomics Journal advance online publication, 2 August 2011; doi:10.1038/tpj.2011.30.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.